. . . . . . . "approved"@en . . "An indole derivative effective in schizophrenia and other psychoses and possibly useful in the treatment of the aggressive type of undersocialized conduct disorder. Molindone has much lower affinity for D2 receptors than most antipsychotic agents and has a relatively low affinity for D1 receptors. It has only low to moderate affinity for cholinergic and alpha-adrenergic receptors. Some electrophysiologic data from animals indicate that molindone has certain characteristics that resemble those of clozapine. (From AMA Drug Evaluations Annual, 1994, p283)"@en . "Rapidly absorbed from the gastrointestinal tract following oral administration."@en . . . . . "Molindone is used for the management of the manifestations of psychotic disorders."@en . "Molindonum"@en . . "7416-34-4"@en . . . . . "Molindone"@en . . . "SID50111112"@en . "\"DrugSyn.org\":http://www.drugsyn.org/Molindone.htm"@en . "SID26755691"@en . . . . . "Molindona"@en . . " "@en . "The exact mechanism has not been established, however, based on electroencephalogram (EEG) studies, molindone is thought to act by occupying (antagonizing) dopamine (D2) receptor sites in the reticular limbic systems in the brain, thus decreasing dopamine activity. Decreased dopamine activity results in decreased physiological effects normally induced by excessive dopamine stimulation, such as those typically seen in manifestations of psychotic disorders."@en . . . "(+-)-molindone"@en . . . . "Human metabolic studies show molindone to be rapidly absorbed and metabolized when given orally. There are 36 recognized metabolites with less than 2-3% unmetabolized molindone being excreted in urine and feces."@en . . . . . "SID90341242"@en . . . . . . . . . . . . . . . "Moban"@en . . . . . "Humans and other mammals"@en . . "Molindone"@en . .